Blueprint Medicines (BPMC) PT Raised to $102 at Morgan Stanley
Tweet
Share
E-mailGet Alerts BPMC Hot Sheet
Price: $129.46 --0%
Rating Summary:
11 Buy, 18 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 9 | New: 8
Rating Summary:
11 Buy, 18 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 9 | New: 8
Join SI Premium – FREE
Morgan Stanley analyst Judah Frommer raised the price target on Blueprint Medicines (NASDAQ: BPMC) to $102.00 (from $100.00) while maintaining a Equalweight rating.
You May Also Be Interested In
- Nebius Group (NBIS) PT Raised to $300 at Compass Point
- Brinker Int'l (EAT) PT Raised to $250 at Morgan Stanley
- Sprout Social Inc. (SPT) PT Raised to $11 at Morgan Stanley
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
